CoChat

A randomised controlled trial of the clinical effectiveness and cost-effectiveness of the levonorgestrel-releasing intrauterine system in primary care against standard treatment for menorrhagia: the ECLIPSE trial

Open access
Gupta, Janesh K, Daniels, Jane P, Middleton, Lee J, Pattison, Helen M, Prileszky, Gail, Roberts, Tracy E, Sanghera, Sabina, Barton, Pelham, Gray, Richard, Kai, Joe, on behalf of the ECLIPSE Collaborative Group · 2015 · Health Technology Assessment

The DOI matches its Crossref record; 106 of the 107 references it cites were found in a registry or an index.

Abstract

Background: Heavy menstrual bleeding (HMB) is a common problem, yet evidence to inform decisions about initial medical treatment is limited. Objectives: To assess the clinical effectiveness and cost-effectiveness of the levonorgestrel-releasing intrauterine system (LNG-IUS) (Mirena ® , Bayer) compared with usual medical treatment, with exploration of women’s perspectives on treatment. Design: A pragmatic, multicentre randomised trial with an economic evaluation and a longitudinal qualitative study. Setting: Women who presented in primary care. Participants: A total of 571 women with HMB. A purposeful sample of 27 women who were randomised or ineligible owing to treatment preference participated in semistructured face-to-face interviews around 2 and 12 months after commencing treatment. Interventions: LNG-IUS or usual medical treatment (tranexamic acid, mefenamic acid, combined oestrogen–progestogen or progesterone alone). Women could subsequently swap or cease their allocated treatment. Outcome measures: The primary outcome was the patient-reported score on the Menorrhagia Multi-Attribute Scale (MMAS) assessed over a 2-year period and then again at 5 years. Secondary outcomes included general quality of life (QoL), sexual activity, surgical intervention and safety. Data were analysed using iterative constant comparison. A state transition model-based cost–utility analysis was undertaken alongside the randomised trial. Quality-adjusted life-years (QALYs) were derived from the European Quality of Life-5 Dimensions (EQ-5D) and the Short Form questionnaire-6 Dimensions (SF-6D). The intention-to-treat analyses were reported as cost per QALY gained. Uncertainty was explored by conducting both deterministic and probabilistic sensitivity analyses. Results: The MMAS total scores improved significantly in both groups at all time points, but were significantly greater for the LNG-IUS than for usual treatment [mean difference over 2 years was 13.4 points, 95% confidence interval (CI) 9.9 to 16.9 points; p < 0.001]. However, this difference between groups was reduced and no longer significant by 5 years (mean difference in scores 3.9 points, 95% CI –0.6 to 8.3 points; p = 0.09). By 5 years, only 47% of women had a LNG-IUS in place and 15% were still taking usual medical treatment. Five-year surgery rates were low, at 20%, and were similar, irrespective of initial treatments. There were no significant differences in serious adverse events between groups. Using the EQ-5D, at 2 years, the relative cost-effectiveness of the LNG-IUS compared with usual medical treatment was £1600 per QALY, which by 5 years was reduced to £114 per QALY. Using the SF-6D, usual medical treatment dominates the LNG-IUS. The qualitative findings show that women’s experiences and expectations of medical treatments for HMB vary considerably and change over time. Women had high expectations of a prompt effect from medical treatments. Conclusions: The LNG-IUS, compared with usual medical therapies, resulted in greater improvement over 2 years in women’s assessments of the effect of HMB on their daily routine, including work, social and family life, and psychological and physical well-being. At 5 years, the differences were no longer significant. A similar low proportion of women required surgical intervention in both groups. The LNG-IUS is cost-effective in both the short and medium term, using the method generally recommended by the National Institute for Health and Care Excellence. Using the alternative measures to value QoL will have a considerable impact on cost-effectiveness decisions. It will be important to explore the clinical and health-care trajectories of the ECLIPSE (clinical effectiveness and cost-effectiveness of levonorgestrel-releasing intrauterine system in primary care against standard treatment for menorrhagia) trial participants to 10 years, by which time half of the cohort will have reached menopause. Trial registration: Current Controlled Trials ISRCTN86566246. Funding: This project was funded by the NIHR Health Technology Assessment programme and will be published in full in Health Technology Assessment ; Vol. 19, No. 88. See the NIHR Journals Library website for further project information

Overview

Integrity signals

Registry

Crossref · 10.3310/hta19880

Cites

106 of 106 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 106 references

Research works printed but not linked: 12

  1. National Institute for Health and Care Excellence, 2007, Heavy Menstrual Bleeding: Guideline CG44
  2. Royal College of Obstetrics and Gynaecology (RCOG), 1998, The Initial Management of Menorrhagia – Evidence-Based Clinical Guidelines No. 1
  3. Joint Formulary Committee, 2011, British National Formulary
  4. Gheit, 2009, Bleeding patterns associated with progestin-only contraceptives: a prospective controlled trial comparing Mirena versus progestin only pill, Middle East Fertil Soc J, 14, 216
  5. Kari, 2005, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of Mirena to a Three-Month Administration of Danazol Followed by a 3-Month Observation Period in Women Aged over 30 with Functional Menorrhagia
  6. Muenzen, 2009, A multicenter, randomized, open label, parallel group, active control study to evaluate the efficacy and safety of LNG IUS (Mirena) as compared to medroxyprogesterone acetate during 6 cycles of treatment in patients with idiopathic menorrhagia, BSP Report
  7. National Institute for Health and Care Excellence, 2013, Guide to the Methods of Technology Appraisal
  8. Cohen, 1977, Statistical Power Analysis for the Behavioural Sciences
  9. Shaw, 2007, Randomised comparative trial of thermal balloon ablation and levonorgestrel intrauterine system in patients with idiopathic menorrhagia, Aust N Z J Obstet Gynaecol, 47, 335, 10.1111/j.1479-828X.2007.00747.x · DOI
  10. Belevantsev, Model of transition from anodization to microarc stage, Izv Sib Otd an Khim, 6, 73
  11. Curtis, 2012, Unit Costs of Health and Social Care 2011
  12. National Institute for Health and Care Excellence, 2008, Guide to the Methods of Technology Appraisal

Cited by

See all 399

Metadata

Authors
Gupta, J. K., Daniels, J. P., Middleton, L. J., Pattison, H. M., Prileszky, G., Roberts, T. E., Sanghera, S., Barton, P., Gray, R., Kai, J., & on behalf of the ECLIPSE Collaborative Group
Affiliations
  • Birmingham Women's Hospital (GB)
  • University of Birmingham (GB)
  • Aston University (GB)
  • University of Nottingham (GB)
  • University of Oxford (GB)
Corresponding author
Daniels, Jane P
Venue
Health Technology Assessment
Published
2015-10
Volume
19
Issue
88
Pages
1-118
ISSN
  • 1366-5278 (ISSN-L)
  • 2046-4924
OpenAlex
W2152498789
Cited by
399
References
107
Citations by year
2026: 13 · 2025: 26 · 2024: 25 · 2023: 28 · 2022: 32 · 2021: 53 · 2020: 50 · 2019: 44 · 2018: 48 · 2017: 49 · 2016: 28 · 2015: 3
FWCI
45.25
Type
journal article
Language
en
Open access
Locations
  • Health Technology Assessment (publishedVersion, cc-by)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Repository@Nottingham (University of Nottingham) (publishedVersion, other-oa)
  • Explore Bristol Research (publishedVersion)
  • Repository@Nottingham (University of Nottingham) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Nottingham ePrints (University of Nottingham) (submittedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
  • Bristol Research (University of Bristol) (submittedVersion)
Funders
Health Technology Assessment programme (02/06/02)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Menstrual Health and Disorders
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Keywords
levonorgestrel-releasing intrauterine system, menorrhagia, primary care, cost-effectiveness, quality of life, patient-reported outcomes, tranexamic acid, mefenamic acid
MeSH terms
Antifibrinolytic Agents, Contraceptive Agents, Female, Cost-Benefit Analysis, Female, Humans, Intrauterine Devices, Medicated, Menorrhagia, Primary Health Care, Surveys and Questionnaires, Technology Assessment, Biomedical, Tranexamic Acid, Treatment Outcome, Levonorgestrel, Quality-Adjusted Life Years

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A randomised controlled trial of the clinical effectiveness and cost-effectiveness of the levonorgestrel-releasing intrauterine system in primary care against standard treatment for menorrhagia: the ECLIPSE trial. https://app.cochat.ai/papers/10.3310/hta19880
The paper
Gupta, J. K., Daniels, J. P., Middleton, L. J., Pattison, H. M., Prileszky, G., Roberts, T. E., Sanghera, S., Barton, P., Gray, R., Kai, J., & on behalf of the ECLIPSE Collaborative Group. (2015). A randomised controlled trial of the clinical effectiveness and cost-effectiveness of the levonorgestrel-releasing intrauterine system in primary care against standard treatment for menorrhagia: the ECLIPSE trial. Health Technology Assessment. https://doi.org/10.3310/hta19880

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.